Free tool
FAERS Monitor: Bimzelx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761151 or its brand name (Bimzelx, Bimekizumab-Bkzx). Reports on generic versions are filed under their own applications.
Reports
26,321
Serious
8,343
32% of reports
Hospitalization
2,266
Death reported
184
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue4,798
- psoriasis3,204
- drug ineffective2,544
- off label use2,157
- hidradenitis2,041
- condition aggravated1,885
- psoriatic arthropathy1,876
- injection site pain1,487
- inappropriate schedule of product administration1,205
- therapy interrupted1,187
- pruritus1,119
- pain1,096
- product availability issue881
- oral candidiasis856
- fatigue836
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 13 |
| 2023 | 126 |
| 2024 | 2,720 |
| 2025 | 10,928 |
| 2026 | 12,523 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,838 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hidradenitisSignal | 2,041 | 230.0 | 219.3 | 361,364 |
| oral candidiasisSignal | 856 | 55.5 | 51.8 | 42,804 |
| psoriatic arthropathySignal | 1,876 | 38.7 | 37.0 | 65,759 |
| product availability issueSignal | 881 | 32.1 | 30.1 | 25,536 |
| psoriasisSignal | 3,204 | 20.1 | 19.4 | 56,969 |
| therapy interruptedSignal | 1,187 | 13.5 | 12.7 | 13,520 |
| product dose omission issueSignal | 4,798 | 13.2 | 12.9 | 54,140 |
| inappropriate schedule of product administrationSignal | 1,205 | 5.4 | 5.1 | 4,291 |
| condition aggravatedSignal | 1,885 | 5.0 | 4.8 | 6,040 |
| injection site painSignal | 1,487 | 3.9 | 3.7 | 3,218 |
| pruritusSignal | 1,119 | 2.3 | 2.2 | 862 |
| off label use | 2,157 | 2.0 | 1.9 | 1,073 |
| drug ineffective | 2,544 | 1.5 | 1.5 | 518 |
| pain | 1,096 | 1.4 | 1.3 | 143 |
| fatigue | 836 | 0.9 | 0.8 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.